(Q34494154)

2 August 2017

title

GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model (English)

1 reference

2 August 2017

0 references

1 reference

ChEBI release 2020-05-28

Susan E Alters

1

1 reference

2 August 2017

Bryant McLaughlin

2

1 reference

2 August 2017

Benjamin Spink

3

1 reference

2 August 2017

Tigran Lachinyan

4

1 reference

2 August 2017

Chia-wei Wang

5

1 reference

2 August 2017

Vladimir Podust

6

1 reference

2 August 2017

Volker Schellenberger

7

1 reference

2 August 2017

Willem P C Stemmer

8

1 reference

2 August 2017

language of work or name

English

0 references

publication date

26 November 2012

1 reference

2 August 2017

1 reference

2 August 2017

volume

7

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

e50630

1 reference

Creative Commons Attribution 4.0 International

2 August 2017

copyright license

start time

26 November 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Certolizumab pegol for the treatment of Crohn's disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Enteroendocrine localization of GLP-2 receptor expression in humans and rodents

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Ca2+ and protein kinase C activation of mucin granule exocytosis in permeabilized SPOC1 cells.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Intestinal response to growth factors administered alone or in combination with human [Gly2]glucagon-like peptide 2.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome

6 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050630

Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050630

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050630

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050630

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050630

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050630

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0050630

Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Intestinal growth-promoting properties of glucagon-like peptide-2 in mice.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Deficiency of the intestinal growth factor, glucagon-like peptide 2, in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4+ T cells

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3506575

Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis

9 December 2018

1 reference

12 December 2020

Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2

1 reference

12 December 2020

In Vivoandin VitroDegradation of Glucagon-Like Peptide-2 in Humans1

1 reference

12 December 2020

Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2

1 reference

12 December 2020

Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0050630

Identifiers

DOI

1 reference

2 August 2017

0 references

1 reference

2 August 2017

1 reference